UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~December~~March 31, ~~2024~~2025

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

000-55320

(Commission file number)

NEXIEN BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware

26-2049376

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

4340 E Kentucky Ave., Suite 206, Glendale, CO 80246

(Address of principal executive offices) (Zip Code)

(303) 495-7583

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated filer ☐	Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 70,772,196 shares as at ~~February~~May 1413, 2025.

TABLE OF CONTENTS

Item	Description	Page
	PART I - FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS.	3
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.	15
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.	18
ITEM 4.	CONTROLS AND PROCEDURES.	18

	PART II - OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS.	19
ITEM 1A.	RISK FACTORS.	19
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.	19
ITEM 3.	DEFAULT UPON SENIOR SECURITIES.	19
ITEM 4.	MINE SAFETY DISCLOSURES.	19
ITEM 5.	OTHER INFORMATION.	19
ITEM 6.	EXHIBITS.	20

PART 1 - FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

Nexien BioPharma, Inc.

Consolidated Balance Sheets

	December 31, 2024			June 30, 2024
	March 31, 2025			June 30, 2024
	(Unaudited)			(Audited)
Current Assets
Cash	$	18,~~306~~285		$	4,183
Total Current Assets		18,~~306~~285			4,183
Total Assets	$	18,~~306~~285		$	4,183
Liabilities and Stockholders’ (Deficit)
Current Liabilities
Accounts payable and accrued expenses	$	7283,~~985~~426		$	53,178
Due to officer		7898,400			58,400
Convertible note payable - related party		70,000			65,000
Convertible note payable - net of discount of $4,508 (December 31, 2024) and $6,044 (June 30, 2024)		202,612			188,854
Convertible note payable - net of discount of $145 (March 31, 2025) and $6,044 (June 30, 2024)		206,975			188,854
Convertible note payable		~~202~~206,~~612~~975			188,854
Total Current Liabilities		~~423~~458,~~997~~801			365,432
Total Liabilities		~~423~~458,~~997~~801			365,432
Commitments and Contingencies		-			-
Stockholders’ (Deficit)
Preferred stock - $.0001 par value; 10,000,000 authorized; none issued-					-
Preferred stock - $.0001 par value; 10,000,000 authorized; none issued		-			-
Common stock - $.0001 par value; 200,000,000 shares authorized; 70,772,196 (December 31, 2024) and 70,472,196 (June 30, 2024) shares issued and outstanding		7,077			7,047
Common stock - $.0001 par value; 200,000,000 shares authorized;70,772,196 (March 31, 2025) and 70,472,196 (June 30, 2024) shares issued and outstanding		7,077			7,047
Additional paid in capital		11,~~176~~178,~~181~~448			11,166,177
Accumulated deficit		(11,~~605~~636,~~949~~041	)		(11,534,473	)
Total Stockholders’ (Deficit)		(~~422~~450,~~691~~516	)		(361,249	)
Total Liabilities and Stockholders’ (Deficit)	$	18,~~306~~285		$	4,183

See accompanying notes to these consolidated financial statements.

Nexien BioPharma, Inc.

Consolidated Statements of Operations

Three and ~~Six~~Nine Months Ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024

(Unaudited)

	2024			2023			2024			2023
	2025			2024			2025			2024
	Three months ended						~~Six~~Nine months ended
	December 31,						December 31,
	March 31,						March 31,
	2024			2023			2024			2023
	2025			2024			2025			2024
Revenue	$	-		$	-		$	-		$	-
Operating expenses
Professional fees		169,~~020~~340			56,~~625~~665			2838,~~700~~040			2127,~~165~~830
General and administrative		84,~~007~~960			79,~~811~~282			1115,~~037~~997			5463,~~266~~548
Total operating expenses		2414,~~027~~300			1315,~~436~~947			3954,~~737~~037			7591,~~431~~378
Other income (expense)
Interest expense		(11,~~131~~429	)		(710,~~521~~238	)		(2132,~~381~~810	)		(1525,~~042~~280	)
Amortization of discount on convertible notes		(4,~~314~~363	)		(326,~~561~~978	)		(1014,~~358~~721	)		(835,~~963~~941	)
Total other income (expense)		(15,~~445~~792	)		(1137,~~082~~216	)		(3147,~~739~~531	)		(2461,~~005~~221	)
Net loss	$	(3930,~~472~~092	)	$	(2453,~~518~~163	)	$	(71101,~~476~~568	)	$	(99152,~~436~~599	)
Loss per share - basic and diluted	$	(0.00000	)	$	(0.00001	)	$	(0.00001	)	$	(0.00002	)
Weighted average shares outstanding - basic and diluted		70,~~765~~772,~~603~~196			6566,~~107~~384,~~361~~284			70,~~618~~668,~~098~~899			6465,~~840~~353,~~502~~218

See accompanying notes to these consolidated financial statements.

Nexien BioPharma, Inc.

Consolidated Statements of Stockholders’ (Deficit)

~~Six~~Nine Months Ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024

(Unaudited)

	Shares		Common Stock		Additional Paid in Capital		Stock Payable			Accumulated Deficit			Total Stockholders’ (Deficit)
Nine Months Ended March 31, 2025
Balance, June 30, 2024		70,472,196	$	7,047	$	11,166,177	$	-		$	(11,534,473	)	$	(361,249	)
Imputed interest on related party advance		-		-		1,502		-			-			1,502
Net (loss)		-		-		-		-			(32,004	)		(32,004	)
Balance, September 30, 2024		70,472,196		7,047		11,167,679		-			(11,566,477	)		(391,751	)
Common stock issued for loan consideration		300,000		30		6,570		-			-			6,600
Imputed interest on related party advance		-		-		1,932		-			-			1,932
Net (loss)		-		-		-		-			(39,472	)		(39,472	)
Balance, December 31, 2024		70,772,196	$	7,077	$	11,176,181	$	-		$	(11,605,949	)	$	(422,691	)
Imputed interest on related party advance		-		-		2,267		-			-			2,267
Net (loss)		-		-		-		-			(30,092	)		(30,092	)
Balance, March 31, 2025		70,772,196	$	7,077	$	11,178,448	$	-		$	(11,636,041	)	$	(450,516	)
Nine Months Ended March 31, 2024
Balance, June 30, 2023		64,022,196	$	6,402	$	10,986,201	$	50,750		$	(11,295,360	)	$	(252,007	)
Common stock issued to officers		750,000		75		50,675		(50,750	)		-			-
Common stock to be issued to officers		-		-		-		35,000			-			35,000
Imputed interest on related party advance		-		-		1,125		-			-			1,125
Net (loss)		-		-		-		-			(74,918	)		(74,918	)
Balance, September 30, 2023		64,772,196		6,477		11,038,001		35,000			(11,370,278	)		(290,800	)
Balance		64,772,196		6,477		11,038,001		35,000			(11,370,278	)		(290,800	)
Common stock issued to officers		500,000		50		34,950		(35,000	)		-			-
Imputed interest on related party advance		-		-		1,125		-			-			1,125
Net (loss)		-		-		-		-			(24,518	)		(24,518	)
Balance, December 31, 2023		65,272,196	$	6,527	$	11,074,076	$	-		$	(11,394,796	)	$	(314,193	)
Balance		65,272,196	$	6,527	$	11,074,076	$	-		$	(11,394,796	)	$	(314,193	)
Common stock issued as loan consideration		2,200,000		220		13,265		-			-			13,485
Discount on convertible debt		-		-		6,515		-			-			6,515
Imputed interest on related party advance		-		-		1,265		-			-			1,265
Beneficial conversion feature - related party debt		-		-		20,800		-			-			20,800
Net (loss)		-		-		-		-			(53,163	)		(53,163	)
Balance, March 31, 2024		67,472,196	$	6,747	$	11,115,921	$	-		$	(11,447,959	)	$	(325,291	)
Balance		67,472,196	$	6,747	$	11,115,921	$	-		$	(11,447,959	)	$	(325,291	)

See accompanying notes to these consolidated financial statements.

Nexien BioPharma, Inc.

Consolidated Statements of Cash Flows

~~Six~~Nine Months Ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024

(Unaudited)

	2024			2023
	2025			2024
Cash flows from operating activities
Net loss	$	(71101,~~476~~568	)	$	(99152,~~436~~599	)
Adjustments to reconcile net loss to net cash used in operating activities
Imputed interest on related party advances		35,~~434~~701			23,~~250~~515
Stock issued to officers and director		-			35,000
Benefical convertible feature-related party debt		-			20,800
Amortization of discount on convertible debt - related		-			8,963
Amortization of discount on convertible debt		1014,~~358~~721			-6,178
Changes is assets and liabilities
(Increase) decrease in prepaids		-			73,~~980~~780
Increase in accounts payable and accrued expenses		1930,~~807~~248			1220,~~715~~883
Cash used in operating activities		(3750,~~877~~898	)		(3253,~~528~~480	)
Cash flows from investing activities
Cash used in investing activities		-			-
Cash flows from financing activities
Cash proceeds from related party advance		2040,000			-8,400
Cash proceeds from related party note		5,000			-
Cash proceeds from convertible note		10,000			-20,000
Cash provided by financing activities		3555,000			-28,400
Net increase in cash and cash equivalents		(24,~~877~~102	)		(3225,~~528~~080	)
Cash and cash equivalents, beginning of period		4,183			35,147
Cash and cash equivalents, end of period	$	18,~~306~~285		$	210,~~619~~067
Supplemental disclosure of non-cash investing and
Supplemental disclosure of non-cash investing and financing activities
financing activities
Shares issued to officers for services from stock payable	$	-		$	50,750
Shares issued for loan consideration	$	6,600		$	-
Shares issued to officers for services from stock payable	$	-		$	50,750
Debt discount on convertible debt	$	-		$	20,000
Supplemental cash flow items
Cash paid for interest	$	-		$	-
Cash paid for income taxes (net)	$	-		$	-

See accompanying notes to these consolidated financial statements.

NEXIEN BIOPHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 – Nature of Business and Basis of Presentation

Nexien BioPharma, Inc. (the “Company” or “Nexien”) was incorporated in the State of Michigan on November 10, 1952 as Gantos, Inc., and reincorporated in the State of Delaware in 2008, changing its name to Kinder Holding Corp. In October 2017, the Company completed a reverse acquisition of Intiva BioPharma Inc., a Colorado corporation (“BioPharma”), incorporated on March 27, 2017, through an exchange of shares (the “Share Exchange Transaction”) and changed its name to Intiva BioPharma Inc. In September 2018, the Company changed its name to Nexien BioPharma, Inc.

As a result of the Share Exchange Transaction, BioPharma became a wholly-owned subsidiary of the Company. Since this transaction resulted in the existing shareholders of BioPharma acquiring control of the Company, for financial reporting purposes, the business combination has been accounted for as an additional capitalization of the Company (a reverse acquisition with BioPharma as the accounting acquirer). The operations of BioPharma were the only continuing operations of the Company.

BioPharma was incorporated to pursue pre-clinical and drug development activities, in accordance with U.S. Food and Drug Administration (“FDA”) protocols, for certain pharmaceutical formulations that include cannabinoids. It is pursuing the formulation and development of drugs containing cannabinoids for the treatment of various diseases, disorders and medical conditions, and owns a license covering certain intellectual property, including certain patent applications, and has filed three of its own provisional patent applications for other drugs that include cannabinoids and other substances, including terpenes, that are intended to be developed with the objective of treating certain medical conditions and disorders. It was formed as a corporate subsidiary of the Colorado corporation Kanativa USA Inc. (“Kanativa USA”), which is a subsidiary of the Ontario, Canada corporation, Kanativa Inc.

Principles of Consolidation

The accompanying consolidated financial statements include BioPharma and its wholly owned subsidiaries: Intiva BioPharma Inc. (a Colorado corporation), NexN Inc. (“NexN”) and NexDM Inc. (collectively the “Company”), and were prepared from the accounts of the Company in accordance with accounting principles generally accepted in the United States of America (US GAAP). All significant intercompany transactions and balances have been eliminated on consolidation.

Note 2 - Going Concern Uncertainty

The accompanying financial statements have been prepared in conformity with US GAAP, which contemplates the continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception of $11,~~605~~636,~~949~~041. The development of pharmaceuticals with the objective of obtaining approval by the FDA and other international regulatory authorities is not a short-term endeavor for any specific drug candidate. It also requires extremely significant amounts of capital funding for clinical trials and other matters. At ~~December~~March 31, ~~2024~~2025, the Company had a working capital deficit of $~~422~~450,~~691~~516. The Company will require significant additional capital to fund the implementation and execution of its business plan. This capital, which likely will be millions of dollars for a single drug candidate, will be required for research, regulatory applications, and clinical trials. At the present time, the Company does not have any commitments or known sources for this level of funding. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

NEXIEN BIOPHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 3 – Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents

For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at ~~December~~March 31, ~~2024~~2025.

Valuation of Long-Lived Assets

The Company reviews the recoverability of its long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The Company’s primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

Fair Value of Financial Instruments

FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At ~~December~~March 31, ~~2024~~2025, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates.

Fair Value Measurements

The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are:

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

Level 2: Inputs to the valuation methodology include:

	●	Quoted prices for similar assets or liabilities in active markets;
	●	Quoted prices for identical or similar assets or liabilities in inactive markets;
	●	Inputs other than quoted prices that are observable for the asset or liability;
	●	Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

NEXIEN BIOPHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 3 – Summary of Significant Accounting Policies (continued)

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The assets or liabilities fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period ~~that~~when the transfers occur. For the periods ended ~~December~~March 31, ~~2024~~2025 and June 30, 2024, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels.

At ~~December~~ March 31, ~~2024~~2025 and June 30, 2024, no assets or liabilities were required to be measured at fair value on a recurring basis.

Earnings per Common Share

The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. At ~~December~~March 31, ~~2024~~2025, there were potentially dilutive securities convertible into shares of common stock comprised of (i) stock options – convertible into 7,995,000 shares, (ii) warrants – convertible into 5,~~529~~181,~~409~~897 shares and (iii) promissory notes – convertible into 3768,~~771~~091,~~826~~804 shares.

Income Taxes

The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

Revenue Recognition

The Company has adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

Research and Development Expenses

Research and development expenses are charged to operations as incurred. There were no research and development expenses incurred during the ~~six~~ nine and three months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024.

NEXIEN BIOPHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 3 – Summary of Significant Accounting Policies (continued)

Advertising Expenses

Advertising expenses are charged to operations as incurred. There were no advertising expenses incurred during the ~~six~~nine and three months ended ~~December~~ March 31, ~~2024~~2025 and ~~2023~~2024.

Stock-based compensation

Pursuant to FASB ASC 718, all share-based payments to employees, including grants of employee stock options, are recognized in the statement of operations based on their fair values.

Issuance of shares for non-cash consideration

The Company accounts for the issuance of equity instruments to acquire goods and/or services based on the fair value of the goods and services or the fair value of the equity instrument at the time of issuance, whichever is more reliably determinable. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of the standards issued by the FASB. The measurement date for the fair value of the equity instruments issued is determined as the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.

Reclassifications

Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation.

Recent Accounting Pronouncements

Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial position or results of operations. Management has evaluated accounting standards and interpretations issued but not yet effective as of ~~December~~March 31, ~~2024~~2025, and does not expect such pronouncements to have a material impact on the Company’s financial position, operations, or cash flows.

Note 4 – License Agreements

Accu-Break License Agreement

In February 2018, the Company obtained a worldwide exclusive license with respect to a proprietary delivery system for cannabinoid-based medications from Accu-Break Pharmaceuticals Inc (Accu-Break), whose President was an affiliate of the Company as of the date of the agreement. The Company paid $65,000 in cash to the licensor pursuant to the terms of the agreement and issued shares of common stock, valued at $35,000, as final payment due in August 2019. The Company is required to pay milestone payments upon obtaining regulatory approval of pharmaceutical licensed products and royalties based upon sales of licensed products and may grant sublicenses under the terms of the agreement. Although the Company has previously recognized an impairment of its capitalized costs for the license agreement under US GAAP, it retains its rights under the Accu-Break license agreement.

NEXIEN BIOPHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 5– Stockholders’ Equity

Common stock

During the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025, the Company issued shares of its common stock as follows:

●

300,000 shares to a non-related lender as consideration for a loan to the Company (See note 6). The shares were valued at $6,600 ($0.022 per share) based on the trading price of the Company’s common stock as of the date of the loan.

During the ~~six~~nine months ended ~~December~~March 31, ~~2023~~2024, the Company issued shares of its common stock as follows:

● 1,250,000 shares (500,000 to each of the Company’s Chief Executive Officer and Chief Financial Officer and 250,000 to the Company’s Chief Operating Officer) as consideration for their services to the Company during the six months ended December 31, 2023. The shares were valued at $85,750, based on the closing trading price of the Company’s common stock as of the date of Board authorization for the issuance.

	●	1,250,000 shares (500,000 to each of the Company’s Chief Executive Officer and Chief Financial Officer and 250,000 to the Company’s Chief Operating Officer) as consideration for their services to the Company during the nine months ended March 31, 2024. The shares were valued at $85,750, based on the closing trading price of the Company’s common stock as of the date of Board authorization for the issuance.
	●	2,200,000 shares to Quick Capital, LLC (“Quick Capital”) as consideration for entering into a convertible loan agreement. The shares were valued at $13,485, which is included as a component of discount on convertible debt and is being amortized over the term of the loan in the accompanying March 31, 2024 financial statements (See Note 6).

Options

A summary of option activity during the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 is presented below:

Schedule of Stock Option Activity

	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
Outstanding and exercisable – June 30, 2024		7,995,000	$	0.26		1.7
Granted		-
Exercised		-
Expired/Canceled		-
Outstanding and exercisable -December 31, 2024		7,995,000	$	0.26		1.2
Outstanding and exercisable -March 31, 2025		7,995,000	$	0.26		1.0

Warrants

A summary of warrant activity during the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025 is presented below:

Summary of Warrant Activity

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
Outstanding and exercisable – June 30, 2024		5,529,409		$	0.0429		1.35
Granted		-
Exercised		-
Expired/Canceled		-(347,512	)
Outstanding and exercisable – December 31, 2024		5,529,409		$	0.0429		0.85
Outstanding and exercisable – March 31, 2025		5,181,897		$	0.0489		0.65

NEXIEN BIOPHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 6 – Convertible Notes Payable

Convertible note purchase agreement

(i) On January 18, 2022, the Company entered into a note purchase agreement with Quick Capital pursuant to which the Company issued Quick Capital a twelve-month convertible promissory note, due January 18, 2023, in the principal amount of $170,454 (the “Note”) with interest at the rate of 12% per annum. The Company received net proceeds of $146,750 from the note, after Quick Capital’s legal fees of $3,250, and an original issuance discount of 12% ($20,454). In connection with the Note issuance, Quick Capital was also issued 500,000 restricted shares of the Company’s common stock and a three-year warrant (the “Warrant”) to purchase up to an aggregate of 347,512 restricted shares of the Company’s common stock at an exercise price of $0.075 per share). These issuances were valued using the relative fair value method of the cash received on the note. The Note is convertible into shares of common stock at a conversion price of $0.035 per share.

There is no debt discount at ~~December~~March 31, ~~2024~~2025 and June 30, 2024, as all unamortized debt issuance costs and original issue discount had previously been charged to operations.

In May 2023, the Company and Quick Capital entered into an Amendment and Extension of the Note Purchase Agreement extending the maturity of the Note to June 30, 2023, under the same terms as the original Note, with interest during the extension period accruing at the rate of 12% per annum on the unpaid principal balance from the January 18, 2023, original date of maturity. In consideration of the extension of the Note, the Company issued to Quick Capital 500,000 shares of the Company’s Common Stock valued at $20,000 ($0.04 per share). Quick Capital extended the Note through March 31, ~~2024~~2025, and the Company and Quick Capital are in discussions for further extension of the Note. At ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company recorded accrued interest of $3944,~~508~~551 and $29,308, respectively, on the outstanding principal balance of $170,454.

(ii) On February 14, 2024, the Company entered into a note purchase agreement with Quick Capital pursuant to which the Company issued Quick Capital a six-month convertible promissory note, due August 14, 2024, in the principal amount of $24,444, with simple interest at the rate of 12% per annum (default interest at 24% per annum). The Company received net proceeds of $20,000 from the note, after Quick Capital’s legal fees of $2,000, and an original issuance discount of 10% ($2,444). The note is convertible into shares of common stock at a conversion price of $0.02 per share. In connection with the note issuance, Quick Capital was also issued 2,200,000 restricted shares of the Company’s common stock valued at $13,485. At June 30, 2024, the face amount of the note was included in discount on convertible debt and was being amortized over the term of the loan. At ~~December~~March 31, ~~2024~~2025 and June 30, 2024, the Company has recorded accrued interest of $23,~~553~~276 and $1,090, respectively, on the outstanding principal balance of $24,444, and amortization of discount in the amount of $6,044 and $18,400, respectively. There is no debt discount at ~~December~~March 31, ~~2024~~2025, as all unamortized debt issuance costs and original issue discount had previously been charged to operations.

(iii) On October 3, 2024, the Company entered into a note purchase agreement with Quick Capital pursuant to which the Company issued Quick Capital a convertible promissory note, due six months after the date of issue, in the principal amount of $12,222, with simple interest at the rate of 12% per annum (default interest at 24% per annum). The Company received net proceeds of $10,000 from the note, after Quick Capital’s legal fees of $1,000, and an original issuance discount of 10% ($1,222). The note is convertible into shares of common stock at a fixed conversion price of $0.01 per share. In connection with the note issuance, Quick Capital was also issued 300,000 restricted shares of the Company’s common stock, valued at $6,600 ($0.022 per share) based on the trading price of the Company’s common stock as of the date of the loan. At ~~December~~ March 31, ~~2024~~2025, the Company has recorded debt discount on the note of $8,822 of which $48,~~314~~677, has been amortized and charged to operations during the ~~period~~nine months ended ~~December~~March 31, ~~2024~~2025. At ~~December~~March 31, ~~2024~~2025, the Company recorded accrued interest of $~~358~~719 on the outstanding principal balance of $12,222.

NEXIEN BIOPHARMA, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 6 – Convertible Notes Payable (continued)

Convertible notes payable - related

(i) On November 24, 2020, the Company entered into financing agreements with two individuals, its CEO and a shareholder. Under the agreements, the Company issued unsecured convertible promissory notes due in three years (November 24, 2023) with accrued interest at the rate of 8% per annum, compounded annually. The notes and accrued interest are convertible at the option of the holders at any time into restricted shares of the Company’s common stock at a price of $0.037631, being the volume-weighted average price of the common stock over the 10 trading days immediately preceding the date the notes were funded. The CEO was issued a note in the principal amount of $40,000, which included a $15,000 advance made in October 2020 and an additional loan of $25,000. A stockholder of the Company loaned $25,000 on these terms. Both lenders were also issued three types of warrants, exercisable for a five-year period, at prices of $0.040265, $0.043276, and $0.045157, to purchase a total of 5,181,897 shares. At March 31, 2025, the Company recorded accrued interest of $31,193 on the $65,00 aggregate outstanding principal balance of the two notes.

The Company had recorded the conversion feature as a Beneficial Conversion Feature. The $65,000 fair value of the notes was fully discounted at the date of issuance based on the fair value warrants and beneficial conversion feature, and the expense portion of the notes was amortized over the term of the notes. As the warrants exceeded the value of the notes themselves, the discount is the entire amount of the notes. This fair value has been determined based on the current trading prices of the Company’s common stock. Management has determined that this treatment is appropriate given the uncertain nature of the value of the Company and its stock, and there will be no revaluations until the note is paid or redeemed for stock. The note holders have agreed not to convert the loans unless sufficient shares of common stock are available for conversion.

At ~~December~~ March 31, ~~2024~~2025 and June 30, 2024, $65,000 was due under the financing agreements. During the ~~six~~nine months ended ~~December~~March 31, ~~2023~~2024, $58,~~402~~963, was charged to operations for amortization of the Beneficial Conversion Feature of the related party convertible notes payable.

In November 2024, the noteholders agreed to extend the due date of the loans through December 31, 2024 under the same terms and conditions as the original note and in April 2025 have agreed to further extend the notes through June 30, 2025. The Company has accrued interest on the notes at the default interest rate of 18% per annum from November 24, 2023 through ~~December~~March 31, ~~2024~~2025; has adjusted the conversion price to $0.01 per share.

(ii) In November 2024, the Company entered into a financing agreement with a shareholder. Under the agreement, the Company issued an unsecured convertible promissory note in the amount of $5,000, due six months from date of issuance with accrued interest at the rate of 12% per annum, compounded annually. The note and accrued interest are convertible at the option of the holder at any time into restricted shares of the Company’s common stock at a fixed conversion price of $0.01 per share. At March 31, 2025, the Company recorded accrued interest of $242 on the outstanding principal balance of $5,000.

Note 7 – Related Party Transactions

The Company’s Chief Executive Officer has advanced $7898,400 to the Company for working capital and operating purposes, of which $2040,000 was advanced during the ~~six~~nine months ended ~~December~~March 31, ~~2024~~ 2025. The advances are non-interest bearing and are repayable on demand. At ~~December~~ March 31, ~~2024~~2025 and June 30, 2024, the Company recorded a current liability to the officer of $7898,400 and $58,400, respectively. The Company has recorded imputed interest on the advances at a rate of 10% for the nine month periods ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024 in the amounts of $35,~~434~~ 701 and $23,~~250~~515, respectively.

The Board of Directors authorized the issuance of a total of 2,500,000 shares of common stock of the Company to each of its Chief Executive Officer and Chief Financial Officer, with 250,000 of such shares to be issued to each of them every quarter beginning July 1, 2021 and continuing every three months through October 1, 2023. In June 2022, the Board of Directors authorized the issuance of a total of 1,250,000 shares of common stock to its Chief Operating Officer with 250,000 of such shares to be issued to him every quarter beginning July 1, 2022 and continuing every three months through July 1, 2023. At June 30, 2023, the Company has included as stock payable the $50,750 fair value of the aggregate 750,000 shares due to the officers; these shares were subsequently issued during the three months ended September 30, 2023.13

~~As discussed~~NEXIEN ~~in Note 6~~BIOPHARMA, in November 2020, the Company entered into convertible debt financing agreements with two individuals, its CEO and a shareholder, for aggregate borrowings of $65,000; and in October 2024, entered into a convertible debt financing agreement with a shareholder, for borrowing of $5,000INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 7 – Related Party Transactions (continued)

As discussed in Note 6, in November 2020, the Company entered into convertible debt financing agreements with two individuals, its CEO and a shareholder, for aggregate borrowings of $65,000; and in October 2024, entered into a convertible debt financing agreement with the shareholder, for borrowing of $5,000.

BioPharma was formed as a subsidiary of Kanativa USA, which is a subsidiary of Kanativa Inc. Kanativa USA was issued 24,000,000 shares of BioPharma’s common stock as consideration for its contribution of 100% of the ownership of NexN, and costs and expenses incurred on behalf of BioPharma and capitalized license agreement costs.

The members of the Company’s Board of Directors, its Chief Executive Office and its Chief Financial Officer are also directors and officers of Kanativa Inc., and other subsidiaries and affiliated entities of Kanativa Inc.

Note 8- Commitments and Contingencies

At ~~December~~ March 31, ~~2024~~2025 there were no legal proceedings against the Company.

Note 9 – Subsequent Events

~~In January~~The ~~2025,~~Company ~~the~~has ~~Company’s~~analyzed ~~Chief~~its ~~Executive~~operations ~~Officer~~subsequent to ~~advanced~~March ~~$10~~31,~~000~~ to2025, through the ~~Company~~date ~~for~~these ~~working~~financial ~~capital~~statements were issued, and ~~operating~~has ~~purposes. The~~determined ~~advance~~that isit ~~non-interest~~does ~~bearing~~not ~~and~~have isany ~~repayable~~additional onmaterial subsequent ~~demand~~events to disclose.

The Company has analyzed its operations subsequent to December 31, 2024, through the date these financial statements were issued, and has determined that it does not have any additional material subsequent events to disclose.

MANAGEMENT’S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION

Forward-Looking Statements

The following plan of operation provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Certain statements that the Company may make from time to time, including all statements contained in this report that are not statements of historical fact, constitute “forward-looking statements”. Forward-looking statements may be identified by words such as “plans,” “expects,” “believes,” “anticipates,” “estimates,” “projects,” “will,” “should,” and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new product launches, market position and expenditures. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help you understand our historical results of operations during the periods presented and our financial condition for the ~~six~~nine and three months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024. This MD&A should be read in conjunction with our audited financial statements as of June 30, 2024.

Overview

We are engaged in pursuing pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. We have filed three provisional patent applications, and acquired a license covering certain intellectual property related to a drug delivery system.

As a relatively new business engaged in start-up operations and activities, we will require substantial additional funding to successfully complete any of our drug development programs. At present, we cannot estimate the substantial capital requirements needed to secure regulatory approvals for our drug candidates. We estimate that we will need to raise at a minimum $5040,000 just to maintain our existence as a public company for the remainder of the current fiscal year.

We are a start-up company with no revenues from operations. Notwithstanding our successful raise of $2,076,158, net of offering costs, in equity capital and the receipt of $~~181~~246,750, net of financing costs, from debt issuances during the period from inception to ~~December~~ March 31, ~~2024~~2025 there is substantial doubt that we can continue as an on-going business for the next twelve months without a significant infusion of capital or entering into a business combination transaction. We do not anticipate that we will generate revenues from our research and development activities related to our drug development projects in the near future, due to the protracted revenue model of pursuing pharmaceutical drug development in accordance with the pathway set forth by the FDA. The Company had to cease research and development activities due to the lack of sufficient working capital. While management continues its efforts to raise additional capital for the Company, it is also seeking merger or other business combination or restructuring opportunities.

Results of Operations for the three months ended March ~~December~~ 31, ~~2024~~2025 as compared to ~~December~~March 31, ~~2023~~2024

Net loss for the three months ended ~~December~~March 31, ~~2024~~ 2025 was $3930,~~472~~092, ana ~~increase~~decrease in loss of $1423,~~954~~071 from the net loss of $2453,~~518~~163 reported for the three months ended ~~December~~March 31, ~~2023~~2024.

General and administrative expenses ~~were~~decreased ~~consistent~~by ~~during~~$4,322 in ~~the~~2025 ~~2024~~as ~~and~~compared ~~2023~~to ~~periods~~the comparable 2024 period and consisted predominately of costs and expenses associated with the Company’s maintaining its public company status.

During the three months ended ~~December~~March 31, ~~2024~~2025 and ~~2023~~2024, the Company incurred $4,~~314~~363 and $326,~~561~~978, respectively, for discount related to the convertible debt financings. The amount for the 2024 period included the recognition of $20,800 for the Beneficial Conversion Feature of the repriced conversion rate for related party convertible debt during the 2024 period. Interest expense for the three months ended ~~December~~March 31, ~~2024~~2025 was $11,~~131~~429, and included imputed interest ~~for~~ for non-interest bearing advances from an officer of the Company of $12,~~932~~267. Interest expense for the three months ended ~~December~~March 31, ~~2023~~ ~~was~~2024 was $710,~~521~~238, and included imputed interest for non-interest bearing advances from an officer of the Company of $1,~~125~~265.

There were no research and development costs for the periods ended December 31, 2024 and 2023 due to the Company’s limited financial resources and availability of research personnel.

Professional fees of $16,020 for the three months ended December 31, 2024 increased by $10,395 from $5,625 for the period ended December 31, 2023. Fees for the 2024 and 2023 periods consisted of legal fees for securities related matters and fees for auditor quarterly review and other required tax and regulatory.

~~During the~~There ~~three~~were ~~months~~no ~~ended~~research ~~December~~and ~~31,~~development ~~2024,~~costs ~~the Company issued 300,000 shares of common stock (valued at $6,600) to a non-related lender as consideration~~ for ~~a convertible loan in~~ the periods ~~face amount of $12,222. During the three months~~ ended ~~December~~March 31, ~~2023,~~2025 ~~the~~and ~~Company~~2024 ~~issued 500,000~~due ~~shares of common stock~~ to ~~two officers for services rendered to~~ the Company.’s ~~The~~limited ~~$35,000~~financial ~~value~~resources ~~ascribed~~and toavailability ~~these~~of ~~shares~~research ~~was accrued in the prior 2023 period~~personnel.

~~At December~~Professional 31fees of $9,340 ~~2024~~for ~~and~~the ~~June~~three ~~30,~~months ~~2024~~ended March 31, ~~the~~2025 ~~Company~~increased ~~had~~by ~~outstanding~~$2,675 ~~convertible~~from ~~notes~~$6,665 infor the ~~principal~~period ~~amounts~~ended ofMarch ~~$70~~31,~~000~~ ~~and~~2024. ~~$65,000,~~Fees ~~respectively, to~~for ~~its~~the ~~CEO~~2025 and a2024 ~~shareholder;~~periods ~~and~~consisted ~~convertible~~of ~~notes~~legal fees tofor ~~Quick~~securities ~~Capital~~related inmatters ~~the~~and ~~face~~fees ~~amounts~~for ofauditor ~~$207,120~~quarterly review and ~~$194,898,~~other ~~respectively~~required tax and regulatory.

~~Results of~~During ~~Operations for~~ the ~~six~~three months ended ~~December~~March 31, 2024, asthe Company ~~compared~~issued to2,200,000 ~~December~~shares 31of common stock (valued at $13,485) ~~2023~~to a non-related lender as consideration for a convertible loan in the face amount of $24,444.

~~Net loss~~At ~~for~~March ~~the~~31, ~~six~~2025 ~~months~~and ~~ended~~June ~~December 31~~30, 2024, ~~was~~the ~~$71,476,~~Company ahad outstanding ~~decrease~~convertible notes in ~~loss~~the principal amounts of $2770,~~960~~000 ~~from~~and ~~the~~$65,000, ~~net~~respectively, ~~loss~~to ofits ~~$99,436~~CEO ~~reported~~and ~~for~~a shareholder; and convertible notes to Quick Capital in the ~~six~~face ~~months~~amounts ~~ended~~of ~~December~~$207,120 31and $194,898, ~~2023~~respectively.

~~General and~~Results ~~administrative~~of ~~costs~~Operations ~~were $11,037~~ for the ~~six~~nine months ended March ~~December~~ 31, ~~2024,~~2025 ~~consisting~~as ~~solely~~compared ~~of operating expenses~~ to ~~maintain the~~March ~~Company’s status as a public reporting entity. In comparison, general and administrative costs of $54,266 for the six months ended December~~ 31, ~~2023 includes $35,000 as the value of non-cash stock-based compensation costs for common shares issued to the Company’s officers.~~2024

~~General and~~Net ~~administrative~~loss ~~expenses,~~for ~~exclusive~~the ofnine ~~non-cash~~months ~~compensation~~ended ~~costs~~March 31, ~~were~~2025 was ~~consistent~~$101,568, ~~during~~a ~~the~~decrease ~~2024~~in ~~and~~loss ~~2023~~of ~~periods~~$51,031 ~~and~~from ~~consisted predominately~~the ofnet ~~costs~~loss ~~and~~of ~~expenses~~$152,599 ~~associated~~reported ~~with~~for the ~~Company’s~~nine ~~maintaining~~months ~~its~~ended ~~public~~March ~~company~~31, ~~status~~2024.

~~During the~~General ~~six~~and ~~months~~administrative ~~ended~~costs ~~December~~were 31$15,997 ~~2024 and 2023,~~ for the ~~Company~~nine ~~incurred~~months ~~$10,358~~ended ~~and~~March $831,~~963,~~ ~~respectively~~2025, ~~for~~consisting ~~discount~~solely ~~related~~of tooperating ~~the~~expenses ~~convertible debt~~to ~~financings.~~maintain ~~Interest expense for~~ the ~~six~~Company’s ~~months~~status ~~ended~~as ~~December~~a ~~31,~~public ~~2024~~reporting entity. ~~was~~In ~~$21~~comparison,~~381,~~ general and ~~included~~administrative ~~imputed~~costs ~~interest for non-interest bearing advances from an officer~~ of ~~the Company of~~ $363,~~434.~~548 ~~Interest expense~~ for the ~~six~~nine months ended ~~December~~March 31, ~~2023~~2024 ~~was~~includes $1535,~~042,~~000 ~~and included~~as ~~imputed~~the ~~interest~~value of ~~for~~ non-~~interest~~cash ~~bearing~~stock-based ~~advances~~compensation ~~from~~costs anfor ~~officer~~common ofshares issued to the Company’s ~~of $2,250~~officers.

~~There were~~General noand ~~research~~administrative ~~and~~expenses, ~~development~~exclusive of non-cash compensation costs, ~~for~~were ~~the~~consistent ~~periods~~during ~~ended~~the ~~December~~2025 ~~31,~~and 2024 periods, and ~~2023~~consisted ~~due~~predominately toof costs and expenses associated with the Company’s ~~limited~~maintaining ~~financial resources~~its ~~and~~public ~~availability~~company ~~of research personnel~~status.

~~Professional fees~~During ~~of $28,700 for~~ the ~~six~~nine months ended ~~December~~March 31, 2025 and 2024, the ~~increased~~Company byincurred $714,~~535~~721 ~~from~~and $2135,~~165~~941, respectively, for discount related to the convertible debt financings. The amount for the 2024 period ~~ended~~included ~~December~~the 31recognition of $20,800 ~~2023.~~for ~~Fees~~ the Beneficial Conversion Feature of the repriced conversion rate for related party convertible debt during the 2024 period. Interest expense for the nine months ended March 31, 2025 was $32,810, and ~~2023~~included ~~periods~~imputed ~~consisted~~interest for non-interest bearing advances from an officer of ~~legal~~the ~~fees~~Company of $5,701. Interest expense for ~~securities~~the ~~related~~nine ~~matters~~months ended March 31, 2024 was $25,280, and ~~fees~~included imputed interest for ~~quarterly~~non-interest ~~auditor~~bearing ~~review~~advances ~~and~~from ~~other required~~an ~~tax~~officer ~~and~~of ~~regulatory~~the Company of $3,515.

~~During the~~There ~~six~~were ~~months~~no ~~ended~~research ~~December~~and ~~31,~~development ~~2024,~~costs ~~the Company issued 300,000 shares of common stock (valued at $6,600) to a non-related lender as consideration~~ for ~~a convertible loan in~~ the periods ~~face~~ended ~~amount~~March ~~of $12~~31,~~222.~~ ~~During~~2025 ~~the~~and ~~six~~2024 ~~months~~due ~~ended~~to ~~December 31, 2023,~~ the Company’s ~~issued 1,250,000~~limited ~~shares~~financial ofresources ~~common~~and ~~stock~~availability toof ~~three~~research ~~officers for services rendered to the Company~~personnel.

AtProfessional fees of $38,040 for the nine months ended ~~December~~March 31, ~~2024~~2025 ~~and~~increased ~~June~~by 30$10,210 ~~2024~~from $27,830 for the ~~Company~~comparable ~~had~~2024 ~~outstanding~~period. ~~convertible~~Fees ~~notes~~for in the ~~principal~~2025 ~~amounts~~and of2024 ~~$70,000~~periods ~~and~~consisted ~~$65,000,~~of ~~respectively,~~legal tofees ~~its~~for ~~CEO~~securities ~~and~~related amatters ~~shareholder;~~ and ~~convertible~~fees ~~notes~~for toannual ~~Quick~~audit ~~Capital~~and inquarterly ~~the~~auditor ~~face~~reviews ~~amounts~~and ofother ~~$207,120~~required tax and ~~$194,898, respectively~~regulatory.

~~Liquidity~~During the nine months ended March 31, 2025, the Company issued 300,000 shares of common stock (valued at $6,600) to a non-related lender as consideration for a convertible loan in the face amount of $12,222. During the nine months ended March 31, 2024, the Company issued 1,250,000 shares of common stock to three officers for services rendered to the Company; and ~~Capital~~issued ~~Resources~~2,200,000 shares of common stock (valued at $13,485) to a non-related lender as consideration for a convertible loan in the face amount of $24,444.

At ~~December~~ March 31, ~~2024,~~2025 weand ~~had~~June a30, ~~working capital deficit of $422~~2024,~~691~~ ~~and~~the ~~cash~~Company ofhad outstanding ~~$1,306,~~convertible asnotes ~~compared~~in tothe aprincipal ~~working~~amounts ~~capital deficit~~ of $~~361~~70,~~249~~ 000 and ~~cash of~~ $465,~~183~~000, ~~at June 30~~respectively, ~~2024.~~to ~~The~~its ~~decrease~~CEO inand ~~working~~a ~~capital~~shareholder; ~~was~~and ~~due~~convertible notes ~~primarily~~ to ~~the~~Quick ~~utilization~~Capital ofin ~~existing cash for operating activities during~~ the ~~six~~face ~~months~~amounts ~~ended~~of ~~December 31, 2024. Substantially all available funds were being utilized solely for maintaining corporate operations as a public company. We used~~ $37207,~~877~~120 ~~of cash for operating activities during the six months ended December 31, 2024,~~ and ~~received cash from investing activities of~~ $35194,~~000~~898, ~~during the period~~respectively.

Liquidity and Capital Resources

At March 31, 2025 we had a working capital deficit of $450,516 and cash of $8,285, as compared to a working capital deficit of $361,249 and cash of $4,183 at June 30, 2024. The decrease in working capital was due primarily to the utilization of existing cash for operating activities during the nine months ended March 31, 2025. Substantially all available funds were being utilized solely for maintaining corporate operations as a public company. We used $50,898 of cash for operating activities during the nine months ended March 31, 2025, and received cash from financing activities of $55,000 during the period.

The Company had to cease research and development activities due to the lack of sufficient working capital. While management continues its efforts to raise additional capital for the Company, it is also seeking merger or other business combination or restructuring opportunities.

Our ability to create sufficient working capital to sustain us over the next twelve-month period, and beyond, is dependent on our raising additional equity or debt capital or entering into strategic arrangements with one or more third parties.

There can be no assurance that sufficient capital will be available to us. We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.

During the ~~six~~nine months ended ~~December~~March 31, ~~2024~~2025, the Company’s Chief Executive Officer advanced $2040,000 to the Company for working capital and operating purposes. The advance is non-interest bearing and is repayable upon demand.

Availability of Additional Capital

Notwithstanding our success in raising gross proceeds of $2.1 million from the private sale of equity securities through ~~December~~March 31, ~~2024~~2025, and the completion of a debt financing agreement resulting in the receipt of $~~181~~246,750 net proceeds, there can be no assurance that we will continue to be successful in raising additional funds through equity capital and/or debt financings and have adequate capital resources to fund our operations or that any additional funds will be available to us on favorable terms or in amounts required by us. We estimate that we will require at a minimum $40,000 just to maintain our existence as a public company for the remainder of the current fiscal year.

Any additional equity financing may be dilutive to our stockholders, new equity securities may have rights, preferences or privileges senior to those of existing holders of our shares of Common Stock. Debt or equity financing may subject us to restrictive covenants and significant interest costs.

Capital Expenditure Plan During the Next Twelve Months

Through ~~December~~ March 31, ~~2024~~2025, we raised approximately $2.1 million, in equity capital (including exercised warrants) and $~~181~~246,750, net, in debt financings, and we may be expected to require a minimum of $40,000 in capital during the remainder of the current fiscal year to continue our existence as a public company. There can be no assurance that we will continue to be successful in raising capital in sufficient amounts and/or at terms and conditions satisfactory to the Company. Any revenues are expected to come from our drug development projects, which will take several years if successful. As a result, we will continue to incur operating losses unless and until we have obtained regulatory approval with respect to one of our drug development projects and commence to generate sufficient cash flow to meet our operating expenses. There can be no assurance that we will obtain regulatory approval and the market will adopt our future drugs. In the event that we are not able to successfully: (i) raise equity capital and/or debt financing; or (ii) market our drugs after obtaining regulatory approval, our financial condition and results of operations will be materially and adversely affected. Accordingly, while management continues its efforts to raise additional capital for the Company, it is also seeking a merger or other business combination or restructuring opportunities.

Going Concern Consideration

Our registered independent auditors have issued an opinion on our financial statements as of June 30, 2024 which includes a statement describing our going concern status. This means that there is substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay our bills and meet our other financial obligations. This is because we have not generated any revenues and no revenues are anticipated until we begin marketing any drugs that we successfully develop. Accordingly, we must raise capital from sources other than the actual sale from any drugs that we develop. We must raise capital to continue our drug development activities and stay in business.

Off-Balance Sheet Arrangements

At ~~December~~ March 31, ~~2024~~2025 and June 30, 2024, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities Act of 1934.

Contractual Obligations and Commitments

In February 2018, we obtained a worldwide exclusive license with respect to a proprietary delivery system for cannabinoid-based medications. We paid $65,000 in cash to the licensor pursuant to the terms of the agreement and issued shares of our common stock, valued at $35,000, as final payment due in August 2019. We are required to pay milestone payments upon obtaining regulatory approval of pharmaceutical licensed products and royalties based upon sales of licensed products. We may grant sublicenses under the terms of the agreement.

Critical Accounting Policies

Our significant accounting policies are described in the notes to our financial statements as of ~~December~~March 31, ~~2024~~2025 and are included elsewhere in this report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures.

As of ~~December~~March 31, ~~2024~~2025, the Company’s chief executive officer and chief financial officer conducted an evaluation regarding the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act. Based upon the evaluation of these controls and procedures as provided under the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013), our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report. We did not establish a formal written policy for the approval, identification, and authorization of related party transactions.

Changes in internal controls.

During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Risk Factors in our Form 10-K as filed with the SEC on October 22, 2024, which could materially affect our business, financial condition or future results. The risks described in our Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~During the quarter ended December 31, 2024, we issued and sold the unregistered securities set forth in the table below.~~None

Date		Persons or Class of Persons		Securities		Consideration
October 2024		Quick Capital LLC		300,000 shares of Common Stock		Financing fee

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

We relied upon the exemption from registration contained in Section 4(a)(2) under the Securities Act, as the securities were sold only to investors, sophisticated as to the business of the Company, without the use of general solicitation or advertisingNone. No underwriters or placement agents were used and no commissions were paid in the above stock transactions. A restrictive legend was placed on the certificates evidencing the securities issued in the above transactions.

ITEM 3 4. ~~DEFAULTS~~MINE ~~UPON~~SAFETY ~~SENIOR SECURITIES~~DISCLOSURES

~~None~~Not applicable.

ITEM 4 5. ~~MINE~~OTHER ~~SAFETY DISCLOSURES~~INFORMATION

~~Not applicable.~~None

~~ITEM 5. OTHER INFORMATION~~19

~~None~~ITEM 6. EXHIBITS

Regulation S-K Number		Document
3.1		Certificate of Incorporation (1)
3.2		Certificate of Merger (1)
3.3		Certificate of Amendment to Certificate of Incorporation (1)
3.4		Certificate of Amendment to Certificate of Incorporation (2)
3.5		Certificate of Amendment to Certificate of Incorporation (3)
3.6		Bylaws (1)
10.1		2017 Stock Incentive Plan (2)
10.2		Exclusive License Agreement between the Company and Accu-Break Pharmaceuticals, Inc. (2)
10.3		2018 Equity Incentive Plan (2)
10.4		First Amendment to Exclusive License Agreement between the Company and Accu-Break Pharmaceuticals, Inc. dated September 18, 2018 (3)
10.5		Demand Convertible Promissory Note dated June 11, 2020 to Richard Greenberg (4)
10.6		Convertible Promissory Note and Warrants dated November 24, 2020 to Richard Greenberg (5)
10.7		Note Purchase Agreement dated January 18, 2022 between the Company and Quick Capital, LLC (6)
10.8		Convertible Promissory Note dated January 18, 2022 issued to Quick Capital, LLC (6)
10.9		Common Stock Purchase Warrant dated January 18, 2022 issued to Quick Capital, LLC (6)
10.10		Amendment and Extension of Note Purchase Agreement dated May 8, 2023 (7)
10.11		Note Purchase Agreement dated February 14, 2024 between the Company and Quick Capital, LLC (8)
10.12		Convertible Promissory Note dated February 14, 2024 issued to Quick Capital, LLC (8)
10.13		Amendment and Second Extension of Note Purchase Agreement between the Company and Richard Greenberg dated February 29, 2024 (8)
10.14		Note Purchase Agreement dated October 3, 2024 between the Company and Quick Capital, LLC (9)
10.15		Convertible Promissory Note dated October 3, 2024 issued to Quick Capital, LLC (9)
10.16		Convertible Promissory Note dated November 4, 2024 issued to Alain Bankier (10)
10.17		Amendment and Third Extension of Note Purchase Agreement between the Company and Richard Greenberg dated November 9, 2024 (10)
31.1		Rule 13a-14(a) Certification of Richard Greenberg
31.2		Rule 13a-14(a) Certification of Evan L. Wasoff
32.1		Certification of Richard Greenberg Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Evan L. Wasoff Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101		Financial statements from the Quarterly Report on Form 10-Q of Nexien BioPharma, Inc. for the quarterly period ended March 31, 2025, formatted in XBRL: (i) the Balance Sheets; (ii) the Statements of Operations; (iii) Statements of Stockholders’ (Deficit), (iv) the Statements of Cash Flows and (v) the Notes to Financial Statements (11)
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

ITEM 6. EXHIBITS

(1)	Filed as an exhibit to the registration statement on Form 10 filed November 14, 2014.
(2)	Filed as an exhibit to the Quarterly Report on Form 10-Q filed May 15, 2018.
(3)	Filed as an exhibit to the Annual Report on Form 10-K filed September 28, 2018.
(4)	Filed as an exhibit to the Annual Report on Form 10-K filed September 28, 2020.
(5)	Filed as an exhibit to the Quarterly Report on Form 10-Q filed February 11, 2021.
(6)	Filed as an exhibit to the Current Report on Form 8-K filed January 21, 2022.
(7)	Filed as an exhibit to the Annual Report on Form 10-K filed September 28, 2023.
(8)	Filed as an exhibit to the Quarterly Report on Form 10-Q filed May 15, 2024.
(9)	Filed as an exhibit to the Annual Report on Form 10-K filed October 22, 2024.
(10)	Filed as an exhibit to the Quarterly Report on Form 10-Q filed February 14, 2025.
(11)	In accordance with Rule 406T of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Regulation S-K Number		Document
3.1		Certificate of Incorporation (1)
3.2		Certificate of Merger (1)
3.3		Certificate of Amendment to Certificate of Incorporation (1)
3.4		Certificate of Amendment to Certificate of Incorporation (2)
3.5		Certificate of Amendment to Certificate of Incorporation (3)
3.6		Bylaws (1)
10.1		2017 Stock Incentive Plan (2)
10.2		Exclusive License Agreement between the Company and Accu-Break Pharmaceuticals, Inc. (2)
10.3		2018 Equity Incentive Plan (2)
10.4		First Amendment to Exclusive License Agreement between the Company and Accu-Break Pharmaceuticals, Inc. dated September 18, 2018 (3)
10.5		Demand Convertible Promissory Note dated June 11, 2020 to Richard Greenberg (4)
10.6		Convertible Promissory Note and Warrants dated November 24, 2020 to Richard Greenberg (5)
10.7		Note Purchase Agreement dated January 18, 2022 between the Company and Quick Capital, LLC (6)
10.8		Convertible Promissory Note dated January 18, 2022 issued to Quick Capital, LLC (6)
10.9		Common Stock Purchase Warrant dated January 18, 2022 issued to Quick Capital, LLC (6)
10.10		Amendment and Extension of Note Purchase Agreement dated May 8, 2023 (7)
10.11		Note Purchase Agreement dated February 14, 2024 between the Company and Quick Capital, LLC (8)
10.12		Convertible Promissory Note dated February 14, 2024 issued to Quick Capital, LLC (8)
10.13		Amendment and Second Extension of Note Purchase Agreement between the Company and Richard Greenberg dated February 29, 2024 (8)
10.14		Note Purchase Agreement dated October 3, 2024 between the Company and Quick Capital, LLC (9)
10.15		Convertible Promissory Note dated October 3, 2024 issued to Quick Capital, LLC (9)
10.16		Convertible Promissory Note dated November 4, 2024 issued to Alain Bankier
10.17		Amendment and Third Extension of Note Purchase Agreement between the Company and Richard Greenberg dated November 9, 2024
31.1		Rule 13a-14(a) Certification of Richard Greenberg
31.2		Rule 13a-14(a) Certification of Evan L. Wasoff
32.1		Certification of Richard Greenberg Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Evan L. Wasoff Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101		Financial statements from the Quarterly Report on Form 10-Q of Nexien BioPharma, Inc. for the quarterly period ended December 31, 2024, formatted in XBRL: (i) the Balance Sheets; (ii) the Statements of Operations; (iii) Statements of Stockholders’ (Deficit), (iv) the Statements of Cash Flows and (v) the Notes to Financial Statements (10)
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

(1)	Filed as an exhibit to the registration statement on Form 10 filed November 14, 2014.
(2)	Filed as an exhibit to the Quarterly Report on Form 10-Q filed May 15, 2018.
(3)	Filed as an exhibit to the Annual Report on Form 10-K filed September 28, 2018.
(4)	Filed as an exhibit to the Annual Report on Form 10-K filed September 28, 2020.
(5)	Filed as an exhibit to the Quarterly Report on Form 10-Q filed February 11, 2021.
(6)	Filed as an exhibit to the Current Report on Form 8-K filed January 21, 2022.
(7)	Filed as an exhibit to the Annual Report on Form 10-K filed September 28, 2023.
(8)	Filed as an exhibit to the Quarterly Report on Form 10-Q filed May 15, 2024.
(9)	Filed as an exhibit to the Annual Report on Form 10-K filed October 22, 2024.
(10)	In accordance with Rule 406T of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

SIGNATURES

20Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGNATURES

	NEXIEN BIOPHARMA, INC.

Dated: May 14, 2025	By:	/s/ Richard Greenberg
		Richard Greenberg, Chief Executive Officer

	By:	/s/ Evan L. Wasoff
		Evan L. Wasoff, Chief Financial Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~21

	NEXIEN BIOPHARMA, INC.
Dated: February 14, 2025	By:	/s/ Richard Greenberg
		Richard Greenberg, Chief Executive Officer
	By:	/s/ Evan L. Wasoff
		Evan L. Wasoff, Chief Financial Officer

Filing Compare · NEXIEN BIOPHARMA, INC.